Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43795
UPID:
MYO1B_HUMAN
Alternative names:
MYH-1c; Myosin I alpha
Alternative UPACC:
O43795; O43794; Q7Z6L5
Background:
Unconventional myosin-Ib, also known as MYH-1c or Myosin I alpha, plays a pivotal role in neuronal development and function. It is involved in essential processes such as cell migration, neurite outgrowth, and vesicular transport, which are critical for the proper functioning of the nervous system.
Therapeutic significance:
Understanding the role of Unconventional myosin-Ib could open doors to potential therapeutic strategies. Its involvement in key neuronal processes makes it a promising target for addressing neurological disorders.